Alivus Life Sciences passes ₹5 dividend, approves FY26 results at AGM
- Alivus Life Sciences shareholders approved a final dividend of ₹5 per share for FY26
- All four ordinary resolutions, including adoption of financials, passed with requisite majority
- Promoter group voted 100% in favor of all agenda items
- Reappointment of Chairman Hiren Patel faced minor opposition from public institutions
*this image is generated using AI for illustrative purposes only.
Alivus Life Sciences shareholders approved a final dividend of ₹5 per equity share for FY26 and adopted the audited financial statements at the company’s 15th annual general meeting on September 8, 2026. The meeting, conducted via video conferencing, saw all four ordinary resolutions pass with requisite majorities.
The board declared the dividend alongside the approval of financial results for the year ended March 31, 2026. Chairman Hiren Patel presided over the session, which was attended by 38 shareholders representing a significant portion of the voting equity. The company also secured approval for the reappointment of Mr. Hiren Patel as a director retiring by rotation.
Voting Results Breakdown
Shareholder participation was high, with votes cast on over 86% of outstanding shares. The promoter group voted in favor of all resolutions without dissent. Public institutional investors also showed strong support, though some opposition was recorded on the director reappointment resolution.
| Resolution | Votes in Favour (%) | Votes Against (%) | Result |
|---|---|---|---|
| Adoption of Financial Statements | 99.9999% | 0.0001% | Passed |
| Declaration of Final Dividend (₹5) | 99.9999% | 0.0001% | Passed |
| Reappointment of Director Hiren Patel | 99.0941% | 0.9059% | Passed |
| Ratification of Cost Auditor Remuneration | 99.9988% | 0.0012% | Passed |
Shareholder Participation Analysis
The promoter and promoter group held 9,18,96,285 shares and voted in favor of all resolutions with 100% support. Public institutions held 1,57,25,917 shares, with 92.8% of these shares polled. While public institutions unanimously supported the financial statements and dividend, they recorded 9,65,103 votes against the reappointment of Mr. Hiren Patel, accounting for 6.61% of their total vote count.
Public non-institutional shareholders held 1,51,49,246 shares, but only 0.83% of these shares were polled. Despite the low turnout from this segment, the votes cast were overwhelmingly in favor of all agenda items. The scrutinizer, Bhadresh Shah and Associates, confirmed that all resolutions were duly passed under the Companies Act, 2013.
Historical Stock Returns for Alivus Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.22% | -2.40% | +3.17% | +49.94% | +48.65% | +104.90% |
How might the dissenting votes from public institutional investors regarding Hiren Patel's reappointment influence future corporate governance dynamics or board composition at Alivus Life Sciences?
Given the ₹5 final dividend for FY26, what is the projected dividend payout ratio and cash flow outlook for FY27 considering the company's R&D and expansion plans?
What strategic initiatives or capital allocation priorities is Alivus Life Sciences likely to pursue in the coming fiscal year following the approval of its audited financial statements?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
